![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » VALEANT LOSES $2.4M JUDGMENT, REPORTS SECOND-QUARTER LOSS
VALEANT LOSES $2.4M JUDGMENT, REPORTS SECOND-QUARTER LOSS
August 4, 2006
A California court has issued a $2.4 million judgment in a case brought by Caleel+Hayden against Valeant Pharmaceuticals International, Caleel+Hayden said. The lawsuit in Orange County Superior Court challenged Valeant's termination of a distribution
agreement for Valeant's Kinerease skin care product line. Caleel+Hayden argued
that the contract was wrongfully terminated, and was awarded $2.4 million.
Los
Angeles Business
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
21Oct